Global Liposomes Drug Delivery

Liposomes Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphotericin B, Liposomal Paclitaxel), Application (Pharmaceutical, Cosmetic, Food, Farming), End Users (Therapeutic, Clinical) Players and Region - Global Market Outlook to 2026

Liposomes Drug Delivery Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Liposomes Drug Delivery Market Scope?
Liposomes is defined as the small spherical-shaped artificial vesicles, which are synthesized from phospholipids and cholesterol. It is colloidal carriers as well as a range from 0.01 to 5.0 μm in diameter. It is widely used to improve the therapeutic index of established drugs by reducing metabolism and reducing toxicity. New applications for the delivery of new biotechnology products, for instance, recombinant proteins antisense oligonucleotides, as well as cloned genes, are some of the major drivers which are propelling the growth of the market. It is expected to expand at a CAGR of 14.8% from 2018 to 2026

The Liposomes Drug Delivery market study is being classified by Type (Liposomal Doxorubicin, Liposomal Amphotericin B and Liposomal Paclitaxel), by Application (Pharmaceutical, Cosmetic, Food and Farming) and major geographies with country level break-up.

The market is fragmented with numerous players focusing on technique and quality of the product due to which the global liposome drug delivery market can witness an upsurge in the forecast period. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Liposomes Drug Delivery market throughout the predicted period.

Gilead Sciences, Inc., (United States), Pacira (United States), Sun Pharmaceutical (India), Luye Pharma (China), Sigma-Tau Group (Switzerland), Fudan-Zhangjiang (China), Teva Pharmaceutical Industries Ltd. (Israel), CSPC (United States), Novartis International AG (Switzerland) and Kingond Pharm (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Spectrum Pharmaceuticals (United States) and Shanghai New Asia (china).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Liposomes Drug Delivery market by Type, Application and Region.

On the basis of geography, the market of Liposomes Drug Delivery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On April 2019, the Insmed, Inc. (United States) Company has provided provides Update on ARIKAYCE, which is liposome inhalation suspension. This will, in turn, propel the growth of liposome drug delivery mark
On August 2018, the United States Food and Drug Administration (FDA), has published its final guidance for industry on liposome drug products in April 2018. In addition, it finalizes the revised draft guidance for industry Liposome Drug Products

Influencing Market Trend
  • Rapid Advancements in targeted Drug Delivery Systems

Market Drivers
  • Rising Prevalence of Chronic Diseases
  • Technological Advancements and New Product Launches
  • Growth in the Biologics Market

Opportunities
  • Rising Demand from Emerging Economics such as India, China and others
  • Rising Demand for Biosimilars
  • Self-Administration and Home Care

Restraints
  • Risk of Needlestick Injuries

Challenges
  • Problem related to Pricing Pressure


Key Target Audience
Manufacturers of Liposome Drug Delivery, Suppliers of Liposome Drug Delivery, Wholesalers, Distributors and Retailers of Liposome Drug Delivery, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Liposomal Doxorubicin
  • Liposomal Amphotericin B
  • Liposomal Paclitaxel
By Application
  • Pharmaceutical
  • Cosmetic
  • Food
  • Farming
By End Users
  • Therapeutic
  • Clinical

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases
      • 3.2.2. Technological Advancements and New Product Launches
      • 3.2.3. Growth in the Biologics Market
    • 3.3. Market Challenges
      • 3.3.1. Problem related to Pricing Pressure
    • 3.4. Market Trends
      • 3.4.1. Rapid Advancements in targeted Drug Delivery Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liposomes Drug Delivery, by Type, Application, End Users and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Liposomes Drug Delivery (Value)
      • 5.2.1. Global Liposomes Drug Delivery by: Type (Value)
        • 5.2.1.1. Liposomal Doxorubicin
        • 5.2.1.2. Liposomal Amphotericin B
        • 5.2.1.3. Liposomal Paclitaxel
      • 5.2.2. Global Liposomes Drug Delivery by: Application (Value)
        • 5.2.2.1. Pharmaceutical
        • 5.2.2.2. Cosmetic
        • 5.2.2.3. Food
        • 5.2.2.4. Farming
      • 5.2.3. Global Liposomes Drug Delivery by: End Users (Value)
        • 5.2.3.1. Therapeutic
        • 5.2.3.2. Clinical
      • 5.2.4. Global Liposomes Drug Delivery Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Liposomes Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gilead Sciences, Inc., (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pacira (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Luye Pharma (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sigma-Tau Group (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fudan-Zhangjiang (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CSPC (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kingond Pharm (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Liposomes Drug Delivery Sale, by Type, Application, End Users and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Liposomes Drug Delivery (Value)
      • 7.2.1. Global Liposomes Drug Delivery by: Type (Value)
        • 7.2.1.1. Liposomal Doxorubicin
        • 7.2.1.2. Liposomal Amphotericin B
        • 7.2.1.3. Liposomal Paclitaxel
      • 7.2.2. Global Liposomes Drug Delivery by: Application (Value)
        • 7.2.2.1. Pharmaceutical
        • 7.2.2.2. Cosmetic
        • 7.2.2.3. Food
        • 7.2.2.4. Farming
      • 7.2.3. Global Liposomes Drug Delivery by: End Users (Value)
        • 7.2.3.1. Therapeutic
        • 7.2.3.2. Clinical
      • 7.2.4. Global Liposomes Drug Delivery Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liposomes Drug Delivery: by Type(USD Million)
  • Table 2. Liposomes Drug Delivery Liposomal Doxorubicin , by Region USD Million (2015-2020)
  • Table 3. Liposomes Drug Delivery Liposomal Amphotericin B , by Region USD Million (2015-2020)
  • Table 4. Liposomes Drug Delivery Liposomal Paclitaxel , by Region USD Million (2015-2020)
  • Table 5. Liposomes Drug Delivery: by Application(USD Million)
  • Table 6. Liposomes Drug Delivery Pharmaceutical , by Region USD Million (2015-2020)
  • Table 7. Liposomes Drug Delivery Cosmetic , by Region USD Million (2015-2020)
  • Table 8. Liposomes Drug Delivery Food , by Region USD Million (2015-2020)
  • Table 9. Liposomes Drug Delivery Farming , by Region USD Million (2015-2020)
  • Table 10. Liposomes Drug Delivery: by End Users(USD Million)
  • Table 11. Liposomes Drug Delivery Therapeutic , by Region USD Million (2015-2020)
  • Table 12. Liposomes Drug Delivery Clinical , by Region USD Million (2015-2020)
  • Table 13. South America Liposomes Drug Delivery, by Country USD Million (2015-2020)
  • Table 14. South America Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 15. South America Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 16. South America Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 17. Brazil Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 18. Brazil Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 19. Brazil Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 20. Argentina Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 21. Argentina Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 22. Argentina Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 23. Rest of South America Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 26. Asia Pacific Liposomes Drug Delivery, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 30. China Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 31. China Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 32. China Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 33. Japan Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 34. Japan Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 35. Japan Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 36. India Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 37. India Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 38. India Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 39. South Korea Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 40. South Korea Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 41. South Korea Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 42. Taiwan Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 43. Taiwan Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 44. Taiwan Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 45. Australia Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 46. Australia Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 47. Australia Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 51. Europe Liposomes Drug Delivery, by Country USD Million (2015-2020)
  • Table 52. Europe Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 53. Europe Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 54. Europe Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 55. Germany Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 56. Germany Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 57. Germany Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 58. France Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 59. France Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 60. France Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 61. Italy Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 62. Italy Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 63. Italy Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 64. United Kingdom Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 67. Netherlands Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 68. Netherlands Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 69. Netherlands Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 70. Rest of Europe Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 73. MEA Liposomes Drug Delivery, by Country USD Million (2015-2020)
  • Table 74. MEA Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 75. MEA Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 76. MEA Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 77. Middle East Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 78. Middle East Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 79. Middle East Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 80. Africa Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 81. Africa Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 82. Africa Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 83. North America Liposomes Drug Delivery, by Country USD Million (2015-2020)
  • Table 84. North America Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 85. North America Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 86. North America Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 87. United States Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 88. United States Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 89. United States Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 90. Canada Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 91. Canada Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 92. Canada Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 93. Mexico Liposomes Drug Delivery, by Type USD Million (2015-2020)
  • Table 94. Mexico Liposomes Drug Delivery, by Application USD Million (2015-2020)
  • Table 95. Mexico Liposomes Drug Delivery, by End Users USD Million (2015-2020)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Liposomes Drug Delivery: by Type(USD Million)
  • Table 107. Liposomes Drug Delivery Liposomal Doxorubicin , by Region USD Million (2021-2026)
  • Table 108. Liposomes Drug Delivery Liposomal Amphotericin B , by Region USD Million (2021-2026)
  • Table 109. Liposomes Drug Delivery Liposomal Paclitaxel , by Region USD Million (2021-2026)
  • Table 110. Liposomes Drug Delivery: by Application(USD Million)
  • Table 111. Liposomes Drug Delivery Pharmaceutical , by Region USD Million (2021-2026)
  • Table 112. Liposomes Drug Delivery Cosmetic , by Region USD Million (2021-2026)
  • Table 113. Liposomes Drug Delivery Food , by Region USD Million (2021-2026)
  • Table 114. Liposomes Drug Delivery Farming , by Region USD Million (2021-2026)
  • Table 115. Liposomes Drug Delivery: by End Users(USD Million)
  • Table 116. Liposomes Drug Delivery Therapeutic , by Region USD Million (2021-2026)
  • Table 117. Liposomes Drug Delivery Clinical , by Region USD Million (2021-2026)
  • Table 118. South America Liposomes Drug Delivery, by Country USD Million (2021-2026)
  • Table 119. South America Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 120. South America Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 121. South America Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 122. Brazil Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 123. Brazil Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 124. Brazil Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 125. Argentina Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 126. Argentina Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 127. Argentina Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 128. Rest of South America Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 129. Rest of South America Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 130. Rest of South America Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 131. Asia Pacific Liposomes Drug Delivery, by Country USD Million (2021-2026)
  • Table 132. Asia Pacific Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 133. Asia Pacific Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 134. Asia Pacific Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 135. China Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 136. China Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 137. China Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 138. Japan Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 139. Japan Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 140. Japan Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 141. India Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 142. India Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 143. India Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 144. South Korea Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 145. South Korea Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 146. South Korea Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 147. Taiwan Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 148. Taiwan Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 149. Taiwan Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 150. Australia Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 151. Australia Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 152. Australia Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 156. Europe Liposomes Drug Delivery, by Country USD Million (2021-2026)
  • Table 157. Europe Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 158. Europe Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 159. Europe Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 160. Germany Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 161. Germany Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 162. Germany Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 163. France Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 164. France Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 165. France Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 166. Italy Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 167. Italy Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 168. Italy Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 169. United Kingdom Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 170. United Kingdom Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 171. United Kingdom Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 172. Netherlands Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 173. Netherlands Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 174. Netherlands Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 175. Rest of Europe Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 176. Rest of Europe Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 177. Rest of Europe Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 178. MEA Liposomes Drug Delivery, by Country USD Million (2021-2026)
  • Table 179. MEA Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 180. MEA Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 181. MEA Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 182. Middle East Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 183. Middle East Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 184. Middle East Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 185. Africa Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 186. Africa Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 187. Africa Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 188. North America Liposomes Drug Delivery, by Country USD Million (2021-2026)
  • Table 189. North America Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 190. North America Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 191. North America Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 192. United States Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 193. United States Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 194. United States Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 195. Canada Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 196. Canada Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 197. Canada Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 198. Mexico Liposomes Drug Delivery, by Type USD Million (2021-2026)
  • Table 199. Mexico Liposomes Drug Delivery, by Application USD Million (2021-2026)
  • Table 200. Mexico Liposomes Drug Delivery, by End Users USD Million (2021-2026)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liposomes Drug Delivery: by Type USD Million (2015-2020)
  • Figure 5. Global Liposomes Drug Delivery: by Application USD Million (2015-2020)
  • Figure 6. Global Liposomes Drug Delivery: by End Users USD Million (2015-2020)
  • Figure 7. South America Liposomes Drug Delivery Share (%), by Country
  • Figure 8. Asia Pacific Liposomes Drug Delivery Share (%), by Country
  • Figure 9. Europe Liposomes Drug Delivery Share (%), by Country
  • Figure 10. MEA Liposomes Drug Delivery Share (%), by Country
  • Figure 11. North America Liposomes Drug Delivery Share (%), by Country
  • Figure 12. Global Liposomes Drug Delivery share by Players 2020 (%)
  • Figure 13. Global Liposomes Drug Delivery share by Players (Top 3) 2020(%)
  • Figure 14. Global Liposomes Drug Delivery share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Gilead Sciences, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 17. Gilead Sciences, Inc., (United States) Revenue: by Geography 2020
  • Figure 18. Pacira (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pacira (United States) Revenue: by Geography 2020
  • Figure 20. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 21. Sun Pharmaceutical (India) Revenue: by Geography 2020
  • Figure 22. Luye Pharma (China) Revenue, Net Income and Gross profit
  • Figure 23. Luye Pharma (China) Revenue: by Geography 2020
  • Figure 24. Sigma-Tau Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Sigma-Tau Group (Switzerland) Revenue: by Geography 2020
  • Figure 26. Fudan-Zhangjiang (China) Revenue, Net Income and Gross profit
  • Figure 27. Fudan-Zhangjiang (China) Revenue: by Geography 2020
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 30. CSPC (United States) Revenue, Net Income and Gross profit
  • Figure 31. CSPC (United States) Revenue: by Geography 2020
  • Figure 32. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. Kingond Pharm (China) Revenue, Net Income and Gross profit
  • Figure 35. Kingond Pharm (China) Revenue: by Geography 2020
  • Figure 36. Global Liposomes Drug Delivery: by Type USD Million (2021-2026)
  • Figure 37. Global Liposomes Drug Delivery: by Application USD Million (2021-2026)
  • Figure 38. Global Liposomes Drug Delivery: by End Users USD Million (2021-2026)
  • Figure 39. South America Liposomes Drug Delivery Share (%), by Country
  • Figure 40. Asia Pacific Liposomes Drug Delivery Share (%), by Country
  • Figure 41. Europe Liposomes Drug Delivery Share (%), by Country
  • Figure 42. MEA Liposomes Drug Delivery Share (%), by Country
  • Figure 43. North America Liposomes Drug Delivery Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Gilead Sciences, Inc., (United States)
  • Pacira (United States)
  • Sun Pharmaceutical (India)
  • Luye Pharma (China)
  • Sigma-Tau Group (Switzerland)
  • Fudan-Zhangjiang (China)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • CSPC (United States)
  • Novartis International AG (Switzerland)
  • Kingond Pharm (China)
Additional players considered in the study are as follows:
Spectrum Pharmaceuticals (United States) , Shanghai New Asia (china)
Select User Access Type

Key Highlights of Report


Jan 2022 244 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Liposomes Drug Delivery Quantitative research analysis
Global Liposomes Drug Delivery Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Liposomes Drug Delivery market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Liposomes Drug Delivery market are Gilead Sciences, Inc., (United States), Pacira (United States), Sun Pharmaceutical (India), Luye Pharma (China), Sigma-Tau Group (Switzerland), Fudan-Zhangjiang (China), Teva Pharmaceutical Industries Ltd. (Israel), CSPC (United States), Novartis International AG (Switzerland) and Kingond Pharm (China), to name a few.
In this highly competitive & fast evolving Liposomes Drug Delivery industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Liposomes Drug Delivery Report?

Have a Query? Click Here

Other Related Reports

Minoxidil Comprehensive Study by Type (2% Minoxidil, 5% Minoxidil), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2030
$ 3500
BCG Vaccine Comprehensive Study by Type (Immune BCG, Therapy BCG), Application (Hospitals, Clinics, Others), Demographics (Pediatrics (0-18 Years), Adults (19-35 Years)) Players and Region - Global M...
$ 3500
Liver Detox Comprehensive Study by Type (Tablets, Capsules, Liquid and Sprays, Others), Distribution Channel (Supermarket, Convenience Stores, Specialty Stores, Online Stores, Other), End User (Indiv...
$ 3350
Antihypertensive Drugs Comprehensive Study by Disease Type (Primary Hypertension, Secondary Hypertension), End-users (Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacy, Hospital Phar...
$ 3750
Legal Cannabis Comprehensive Study by Type (Indoor, Greenhouse), Application (Chronic Pain, Mental Disorders, Cancer, Others), End-Users (Healthcare Industry, Recreational Industry, Others) Players a...
$ 3500
Dual Chamber Syringe Comprehensive Study by Application (Liquid/Powder, Liquid/Liquid), Indication (Hemophilia, Schizophrenia, Diabetes, Erectile Dysfunction, Endometriosis, Others), Size (<1 ml, 1 m...
$ 3650